Jubilant Therapeutics Corporate Deck_Non-Con_May2022

1. Company Presentation
May 2022

2. Forward Looking Statement
Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress
and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-
looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to
numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-
looking statements. Jubilant Therapeutics Inc., may, from time to time, make additional written and oral forward-looking statements, including statements
contained in the company’s filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking
statements to reflect actual results, changed assumptions or other factors. Jubilant Therapeutics Inc., and its affiliated companies, make no representations or
warranties about the information offered in this presentation. Parties should not rely upon the accuracy of the information contained herein.
2

3. Jubilant Therapeutics is a NJ based clinical stage precision therapeutics company
addressing significant unmet medical needs in oncology and autoimmune diseases
3
Differentiated
Pipeline
Novel first-in-class dual LSD1/HDAC6 inhibitor (JBI-802) with synergistic anti-tumor activity
Potential best-in-class brain penetrant PRMT5 inhibitor (JBI-778) with differentiated safety and exposure
Oral brain penetrant PD-L1 inhibitor – First ever potential checkpoint therapy for brain tumors
Novel PAD4 inhibitor with potential first-in-class profile in tumor metastasis and autoimmune disorders
State-of-the-art
Discovery Engine
Proven discovery engine with structure-based drug discovery expertise and a track record of partnerships
with biotech and large pharma. Rapid discovery capabilities for first-in-class and validated but intractable
targets in oncology & autoimmune diseases. Multiple brain penetrant programs.
Experienced
Leadership
Multiple Near-
Term Catalysts
Dual LSD1/HDAC6 IND accepted by FDA, Phase I/ II trial ongoing
Anticipating the submission of additional INDs in 2022
Premier Academic
Collaborations
Multiple academic collaborations and partnerships with premier institutions including Wistar Institute,
Boston Children’s Hospital, Harvard Medical School and Tel Aviv University
Management Team, Board of Directors, and Scientific Advisory Board comprised of leading experts with
decades of highly relevant experience in drug discovery and development

4. Structured with program specific subsidiaries based on distinct themes and targets
4
Epicore
Dual LSD1/HDAC6
Episcribe
PRMT5
Prodel
PD-L1
Epipad
PAD4
Epigenetic therapy for
REST-driven tumors
Novel mechanism for
GBM and brain
metastases
Brain and tissue specific
checkpoint therapy
First-in-class therapy with no
immune suppression for
autoimmune disorders (and
cancer)
Leveraging Innovation for Precision Medicine

5. TIBEO Platform – Jubilant Therapeutics’ SBDD Discovery Engine
5
Therapeutic Index & Brain Exposure Optimization (TIBEO)
Unique scaffold
designed to
drive SAR
brain penetration
optimization
Therapeutic
index
optimization
Toxicology
AI assisted
patient
selection
ADME
brain focus
Mutation
driven cell
screening
Selectivity
screening
Site-
specific
targeting
First-In-Class
Newly discovered and
previously undruggable
Best-In-Class
Overcomes challenges with
toxicity, limited efficacy and
tissue specific exposure
Computational Modelling
& Crystallization
SBDD
SBDD: Structure-based drug design; SAR: Structure activity relationship; AI: Artificial intelligence; ADME: Absorption, distribution, metabolism, and excretion

6. Differentiated portfolio in oncology & autoimmune diseases
6
PROGRAM INDICATIONS HIT TO LEAD
LEAD
OPTIMIZATION
PRE-CLINICAL
(IND)
CLINICAL MILESTONES
COMMERCIAL
RIGHTS
JBI-802
LSD1/HDAC6
Dual Inhibitor
Neuroendocrine Tumors,
SCLC, AML, MPN, MDS
Phase I/ II
Interim safety
data
2H 2022
(Epicore LLC)
JBI-778
PRMT5 Inhibitor
Glioblastoma, Brain
Metastases, MCL
IND
1H 2022
(Episcribe LLC)
JBI-2174
PD-L1 Inhibitor
Brain tumor and Metastases,
GI Track Cancers
IND
2023
(Prodel LLC)
JBI-1044
PAD4 Inhibitor
RA, HS, Vasculitis, Liver
Metastases
IND
2023
(Epipad LLC)
EGFR1,* Oncology
BRD4* Oncology
Multiple difficult-to-target precision therapeutics oncology programs in discovery stage
1Blueprint Medicines acquired Lengo Therapeutics (Frazier Healthcare entity) for $250M in cash plus $215M in milestone payments
*Economic rights reside with Jubilant Therapeutics’ parent company

7. Experienced Management
Syed Kazmi
President & CEO
Luca Rastelli
CSO
Jeremy Barton
Interim CMO
Rajiv Tyagi
VP & Head, Business Development
Shyam Pattabiraman
VP & CFO
Dhanalakshmi Sivanandhan
AVP & Head, Biology
Sridharan Rajagopal
VP & Head – Medicinal Chemistry
7

8. Board of Directors
Hari Bhartia
Founder of Jubilant Bhartia Group; Global multibillion dollar conglomerate with major presence in healthcare and life
sciences, 4 flagship companies, 42,000 employees
Syed Kazmi President & CEO of Jubilant Therapeutics; 30+ yrs in drug discovery, lead oncology BD&L/M&A at Amgen, Novartis
Robert Glassman Venture Partner, OrbiMed Advisors; 20+ yrs in investment banking, hematologist-oncologist faculty at Weill Cornell
Leila Alland CMO, PMV Pharmaceuticals; 20+ yrs experience clinical research
Arvind Chokhany Group Chief Financial Officer of Jubilant Bhartia Group; 25+ yrs in large multinational institutions
Scientific Advisors and Board of Directors
Scientific Advisors
Ross L. Levine Chief, Molecular Cancer Medicine Service, Memorial Sloan Kettering Cancer Center
William C. Hahn William Rosenberg Professor of Medicine, Dana-Farber Cancer Institute
Julian Downward Associate Research Director, The Francis Crick Institute
Greg Plowman ex Lilly & Genentech R&D Head
8

9. JBI-802
Epicore LLC
(LSD1/HDAC6
Dual Inhibitor)

10. JBI-802 Highlights: Breakthrough in Epigenetic Therapy of REST-driven tumors
10
Differentiation
Clinical opportunities
Efficacy
Safety
Milestones
MOA
First in class mechanism of inhibiting two epigenetic targets in CoREST complex:
Unique pharmacophore leading to faster clearance and better therapeutic index
Novel, oral, potent and selective dual inhibitor of both LSD1 and HDAC6; Targeting stem
cell modulation with LSD1; Modulation of immune suppression with isoform selective
HDAC6 inhibition
AML, MDS, MPN, SCLC and neuroendocrine prostate cancer as a monotherapy
Potential for a combination with checkpoint inhibitors in multiple tumors
Synergistic anti-tumor activity, superior vs either target alone. Enhanced anti-tumor
activity in combination with an immune checkpoint inhibitor
Favorable safety profile with no significant safety concerns or accumulation
IND accepted by FDA, Phase I/II ongoing
PCT patent filed in major territories and expires in 2036

11. 7 Major Markets (7MM) = US + 5 EU Spain, Italy, France, UK , and Germany + Japan
8 Major Markets (8MM) = 7MM+ China
*Haematologica. 2011;96(3):450-453
Potential to address hematological cancers and solid tumors with high unmet needs
11
Indication SoC Unmet Need
Epidemiology
2028 8 Major Markets
Market Size USD B
2028 (F)
8 Major Markets
Acute Myeloid Leukemia
(AML)
FLT3, IDH, Anti –CD33
ADC’s, BCL-2 inhibitors;
Cytarabine, Idarubicin
Treatment for refractory AML,
Safe and effective therapy for
elderly, Treatment for
erythroleukemia and MLL
rearranged
Incidence– 88,454
>60% relapse
~5.08 B
Neuroendocrine Tumors
(NETs)
Lutathera, Immune-
checkpoint therapies,
Afinitor, surufatinib
No curative treatment,
Safe Rx for low grade and
efficacious Rx for high
grade tumors
Prevalence – 465410
~3.41 B
2030 Forecast – 8 Major
Markets
Small Cell Lung Cancer
(SCLC)
Chemotherapy, Immune
checkpoint inhibitors
Therapy options for
refractory patients and OS
Incidence – 236,551
~2.3 B

12. JBI-802 is a novel, potent and selective dual inhibitor of LSD1 and HDAC6
HDAC Isoform
JBI-802
IC50 nM
ACY-1215
IC50 nM
HDAC1 923 58
HDAC2 1560 48
HDAC3 1220 51
HDAC4 7840 7000
HDAC5 4450 5000
HDAC6 11.9 4.7
HDAC7 1720 1400
HDAC8 98.3 1000
HDAC9 5710 10000
HDAC10 2220 NA
HDAC11 1330 10000
JBI-802 is highly selective for HDAC6
JBI-802 has potency for both LSD1 and HDAC6 in the low nM range
HDAC6 Isoform Selectivity
12
LSD1 Potency HDAC6 Potency

13. Dual inhibitor LSD1+HDAC6: a Breakthrough in Epigenetic Therapy of REST-driven tumors
Expansion to MYC amplified tumors define new predictive Biomarker
13
LSD1 and HDAC6 are part of the coREST complex,
therefore potential for synergistic activity targeting
REST-driven tumors
‘802 HDAC6 inhibition decrease both MYC RNA
and Protein expanding anti-tumor activity to MYC
amplified tumors with high unmet need

14. Dual inhibitor LSD1+HDAC6: Mechanism-based improvement of safety
14
Dual synergistic inhibition reduces
thrombocytopenia
HDAC6 inhibition eliminates Anemia
LSD1
HDAC6
X
X
LSD1i 802
0
1
2
3
4
5
6
7
8
9
10
Day 14 Day 29 Day 57
RBC
count
x10
6
±SEM
RBC Modulation: 28 day GLP study in Dog
JBI-802, mg/Kg 0 JBI-802, mg/Kg 0.5 JBI-802, mg/Kg 1 JBI-802, mg/Kg 2
0
50
100
150
200
250
300
350
Day 14 Day 29 Day 57
Platelet
count
x10
3
/uL±SEM
Platelet Modulation: 28 day GLP study in Dog
JBI-802, mg/Kg 0 JBI-802, mg/Kg 0.5 JBI-802, mg/Kg 1 JBI-802, mg/Kg 2
GSK2879552
• decreased platelet ~98% and increased immature Megakariocytes
• decreased RBC and increased reticulocytes

15. JBI-802 has synergistic anti-tumor activity, more robust than either LSD1 or HDAC6 alone
JBI-802, LDS1i or HDAC6i in HEL 92.1.7 Xenografts
0
200
400
600
800
1000
1200
1400
1600
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Avg.
Tumor
Volume,
mm
3
±
SEM
Days
Vehicle control, PO, BID
Vehicle control, IP, QD
JBI-802, 25 mg/kg, PO, BID
JBI-802, 50 mg/kg, PO, BID
ORY-1001, 0.01 mg/kg, PO, QD
ACY-1215, 25 mg/kg, IP, QD
JBI-802 observed to have superior anti-tumor activity
vs inhibition of LSD1 or HDAC6
Kaplan Meier survival plot: HEL 92.1.7 Xenografts
Days
Probability
of
Survival
0 20 40 60
0
20
40
60
80
100
Vehicle control
JBI-802, 50 mg/kg
Dosing stopped (day 29)
Dual inhibition with JBI-802 observed to have a
significant increase in survival
P < 0.0001
mOS
20 days
Vehicle
46 days
JBI-802
Kaplan Meier survival plot: HEL 92.1.7 Xenografts
15

16. JBI-802 is effective as a monotherapy with option for synergistic activity with an α-PD-1
JBI-802
JBI-802 + α-PD-1
α-PD-1 Kaplan Meier survival plot
Days
Probability
of
Survival
0 20 40 60
0
20
40
60
80
100 Vehicle control (po, BID)
Vehicle control (ip, QD)
JBI-802, 50 mg/Kg
α-PD-1 ab, 100 μg/mouse
JBI-802 + αPD-1 ab
JBI-802 in combination with α-PD-1 can achieve tumor
regression
Complete tumor regression achieved in 3/8 animals
JBI-802 observed to improve survival in combination with an
α-PD-1 and demonstrated synergistic anti-tumor activity
mOS
16 – 17 days
Vehicle
22 days
JBI-802
23.5 days
α-PD-1
36.5 days
JBI-802 +
α-PD-1
Vehicle control
(BID)
Vehicle control (QD)
JBI-802 + -PD-1 ab
JBI-802, 50 mg/kg
Kaplan Meier survival plot
-PD-1 ab, 100 µg/mouse
16
JBI-802 alone or in combination with an α-PD-1 in CT-26 Syngeneic Model

17. Phase I Dose escalation Expansion Cohort Potential regulatory pathway
Solid
Tumors
Potential for accelerated approval
based on ORR in single arm trial
SCLC nePC
JBI-802 + Anti-PD-1
JBI-802 clinical development for solid and hematologic malignancies
17
3rd line SCLC
1st line nePC
(3rd line PC)
MTD
2nd line AML
MF post JAK-2
RP2D*
AML: Acute myeloid leukemia
MTD: Maximum tolerated dose
MPN: Myeloproliferative neoplasms
nePC: Neuroendocrine prostate cancer
SCLC: Small cell lung cancer
Accelerated
dose
escalation
*Optimal dose based on PK/PD/Efficacy
Expansion Cohort Potential regulatory pathway
AML/Erythroleukemia
MPN
Hematological trial to
start after R2PD is
identified with safety
run-in at dose of RP2D-1
Hematological
Malignancies

18. Recent publications
Intellectual property
• Patent applications filed in India, Australia, Canada, China, Europe, Hong Kong, Israel, Japan, Korea, USA and South Africa
• Earliest filed patent application will expire 09-May-36
LSD1/HDAC6i: Recent publications, presentations and Intellectual property
Program Indications
2021 2022 2023 2024
1H 2H 1H 2H 1H 2H 1H 2H
JBI-802
LSD1/HDAC6 Dual Inhibitor
Neuroendocrine Tumors,
SCLC, AML, MPN, MDS
Phase I/ II
ongoing
Phase I
Initial Data
18
Dec 2020
Bioorg Med Chem Lett. 2020 Dec 24;34:127763
Article: Novel dual LSD1/HDAC6 inhibitors for
the treatment of multiple myeloma
Dec 2020
The 62nd ASH (American Society oh
Hematology) Annual Meeting and Exposition
Poster: JBI-802: Novel LSD1/HDAC6 inhibitor
with a unique mechanism of action
April 2020
AACR (American Association of Cancer
Research) Annual meeting
Poster: Novel dual small molecule inhibitor
targeting LSD1/HDAC6/8
Phase II
Initial Data

19. JBI-778
Episcribe LLC
(PRMT5
Inhibitor)

20. JBI-778 Highlights: Unique opportunity for Brain metastasis
Differentiation
Clinical opportunities
Efficacy
Safety
Milestones
MOA
Unique PRMT5 substrate competitive binding to activating site unlike third-party
candidates that are SAM competitive. Robust and durable brain penetrant as well as
systemic exposure, favorable safety profile and no limiting drug-drug interaction
Oral, isoform selective inhibitor of PRMT5
Tumors with visceral and brain metastasis including lung, breast, colorectal, kidney and
melanoma. Glioblastomas and hematological malignancies including MCL and NHL
Dose-dependent and significant activity in multiple models. Robust and durable plasma
and brain pharmacokinetics
Preliminary toxicology support superior safety profile. In life phase of GLP toxicity
completed, well tolerated in both rat and dog.
IND filing in 1H 2022
PCT patent filed in major territories and expires in 2038
20

21. High potential for brain penetrant PRMT5 inhibition for CNS cancers
21
Indication SoC Unmet Need
Epidemiology
2027 (F) 7MM*
Market Size USD B
7 Major Markets*
GBM
Gliadel
(carmustine wafer),
temozolomide, and
Avastin (bevacizumab)
Lack of efficacious
therapy; No treatment
for refractory GBM
Incidence – 62,281
5 yr Survival – 5%
2027 forecast
~1.4 B
Brain Metastases Surgery, Chemotherapy
No effective treatment
options available
Incidence – 305000 Potential >10 B
*7 MM = US + 5 EU Spain, Italy, France, UK and Germany + Japan

22. JBI-778 is an oral, highly differentiated, SAM cooperative PRMT5 inhibitor
Sustained and elevated brain exposure
gives unique opportunity for brain
tumors where MTA is not increased by
MTAP deficiency
Binding site for
SAM competitive
inhibitor
Binding site for
SAM cooperative and
substrate competitive
inhibitor
(JBI-778)
22
Safe and tolerated in 4 week GLP tox study with no thrombocytopenia
Bareketain et al. Nature Com 2021
Different binding and MOA with
potential to be less toxic in clinic

23. JBI-778 has anti-proliferative activity across solid and hematological tumor cell lines
23
Strong inhibition of proliferation in lymphoma/leukemia cell lines as well as in multiple solid tumors
Anti-proliferative
Activity
GI50,
µM
SCLC NB/GBM Pancreatic Breast Ovarian Hematological

24. JBI-778 is potent with dose-dependent anti-tumor responses
Dose dependent decrease in tumor size
ED50: < 10 mg/kg BID
Superior tumor inhibition in systemic tumor model
vs GSK3326595
Tumor size after treatment with JBI-778 and GSK3326595
in a systemic lymphoma xenograft model (Z138)
0
500
1000
1500
Days of dosing
Tumor
volume,
mm
3
±SEM
1 4 6
Vehicle control
JBI-778, 10 mg/Kg, BID
JBI-778, 50 mg/Kg BID
JBI-778, 50 mg/Kg, QD
JBI-778, 30 mg/Kg, BID
8 10 13 15
Z-138 Xenograft study:
JBI-778 Dose response
18 20
63
89
97 % inh.
69
24
Tumor size after JBI-778 dose response in a systemic
lymphoma xenograft model (Z138)

25. 0.3
0.5
1.0
2.0
4.0
8.0
16.0
32.0
0.25 0.5 1 2 4 8 10
Brain
conc.,
µM
Time, hrs
JBI-778
50 mg/Kg
0
1
2
3
2 4 8 10
Brain
conc.,
µM
Time, hrs
PRT811*
Brain, µM
JBI-778 demonstrates robust plasma and brain exposure
5 10 25 50
0
2
4
6
8
20
40
60
80
100
JBI-778: Brain vs. Plasma
concentration in mice
Dose, mg/Kg
Conc.,
μM±SEM
Brain
Plasma
@ 0.5 h of dosing
Dose dependent brain and plasma
exposure in mouse models
JBI-778 vs PRT811: Brain exposure in mouse models
*Zhang et al AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 2919
Dose 50 mg/kg
Dose 25 mg/kg
Superior brain exposure and duration with
JBI-778 vs PRT811
PRT-811 vs. JBI-778 PRT-811 JBI-778
PRMT5 IC50 (nM) 3.9 3.4
JBI-778: Brain and plasma concentration
25

26. JBI-778 extends survival in preclinical models for glioblastoma
26
Survival Plot: U87MG Orthotopic Study
Days
Percent
survival
6 12 18 24 30 36 42 48 54 60 66 72 78 84 90 96
0
20
40
60
80
100
JBI-778, 50mg/Kg
Vehicle control
JBI-778, 25 mg/Kg
Temozolamide, 100 mg/Kg
Dosed from day 21 to day 48
Temozolamide:
day 21-25
Number of rows
# of blank lines
# rows with impossible data
# censored subjects
# deaths/events
Median survival
Vehicle control
45
40
0
0
5
42
JBI-778, 50mg/Kg
45
32
0
10
3
96
JBI-778, 25 mg/Kg
45
32
0
9
4
86
Temozolamide, 100 mg/Kg
45
31
0
12
2
98
JBI-778 demonstrates comparable survival to temozolamide in preclinical
models
Survival analysis of JBI-778 vs temozolamide in an intracranial orthotopic model
using human glioma cells (U87MG )
mOS
1.4 mos
Vehicle
3.2 mos
JBI-778
3.3 mos
temozolamide
JBI-778-50mpk BID
Vehicle control

27. JBI-778 is efficacious in syngeneic mouse glioma model
27
• 005 mouse glioma cells are rich in brain tumor–initiating stem cells and formed neurosphere-like
structures
• Highly tumorigenic when injected in hippocampus and show glioma-like histopathology with infiltrative
characteristics (Marumoto et al., 2009)
Note: Study performed at Dr. Dinorah Morvinsky lab, Tel Aviv University, Israel
In vivo efficacy
0 10 20 30 40 50
0
50
100
Mouse GBM 005 orthotopic model:
Ctrl vs JBI-778
Days
Probability
of
Survival Ctrl
JBI-778, 50 mg/kg
Median survival
ctrl
27
JBI-778, 50 mg/kg
35
n=5-8

28. JBI-778 clinical development strategy focused on brain tumors
28
Phase I Dose escalation Expansion Cohort Potential regulatory pathway
Solid
Tumors
Potential for accelerated approval
based on ORR in single arm trial
Brain Metastasis
(NSCLC, Breast)
GBM
R&R Brain Metastasis
2nd line GBM
MTD
Accelerated
dose
escalation
RP2D*
GBM: Glioblastoma
NSCLC: Non-small cell lung cancer
*Optimal dose based on PK/PD/Efficacy
Dose escalation component
• Recruiting patients with controlled brain metastasis
Dose expansion cohorts
• Primary brain tumors: high grade gliomas, option to focus on subset based on dose escalation data.
• Uncontrolled brain metastasis, focusing on NSCLC, post immunotherapy and targeted therapy, ORR
and PFS at 6 months

29. Recent publications
Intellectual property
• Patent application filed in Australia, Brazil, Canada, China, Europe, Hong Kong, India, Israel, Japan, Korea, Mexico, New
Zealand, Russia, Singapore, USA and South Africa
• Earliest filed patent application will expire on 23-Nov-38
PRMT5i: Recent publications, presentations, and Intellectual property
29
April 2021
AACR (American Association of Cancer Research) Annual meeting
Poster: Novel, small molecule PRMT5 Inhibitors for treatment of cancer
Program Indications
2021 2022 2023 2024
1H 2H 1H 2H 1H 2H 1H 2H
JBI-778
PRMT5 Inhibitor
Glioblastoma, Brain
Metastases, MCL
Phase I
Initial Data
IND/Phase I
Initiation
Phase II
Initial Data

30. Prodel LLC
(PD-L1
Inhibitor)

31. PD-L1 Inhibitor Program Highlights: unique brain penetration for brain tumors
31
Differentiation
Clinical opportunities
Efficacy
Safety
Milestones
MOA
Uniquely targets brain tumors to achieve efficacy in tumors resistant to approved anti-PD1/PDL-1
Second series uniquely target GI to achieve superior efficacy compared with other PD1/PDL-1
Short-term exposure and oral dosing offer unique opportunity for long-term maintenance therapy
Oral, highly selective PD-L1 inhibitors to address organ specific bio-distribution: unique
opportunity to target GI and brain tumors
Series with specific biodistributions have potential across head & neck cancer, brain tumors
(GBM & brain metastases), GI tumors (non-dMMR/MSI-H CRC), stomach, colon and liver cancer
Multiple leads showed robust anti-tumor activity comparable to anti-PD-L1 antibodies
Well-tolerated at efficacious doses. Clean profile in Cerep 44 toxicity panel
IND filing in 2023
PCT patent filed in major territories and expires in 2038

32. High potential for brain penetrant immune checkpoint therapies for CNS cancer
32
Indication SoC Unmet Need
Epidemiology
2027 (F) 7MM*
Market Size USD B
7 Major Markets*
GBM
Gliadel
(carmustine wafer),
temozolomide, and
Avastin (bevacizumab)
Lack of efficacious
therapy; No treatment
for refractory GBM
Incidence – 62,281
5 yr Survival – 5%
2027 forecast
~1.4 B
Brain Metastases Surgery, Chemotherapy
No effective treatment
options available
Incidence – 305000 Potential >10 B
*7 MM = US + 5 EU Spain, Italy, France, UK and Germany + Japan

33. Brain penetrant PD-L1 inhibitor: a breakthrough to address brain tumors
33
None of the ICI has shown positive
data in brain tumors
Meta-analysis of 88 studies demonstrate limited
efficacy in glioblastoma or brain metastasis for all
anti-PD1/PD-L1
High grade gliomas have low response rates to
Keytruda
Approved ICI are antibodies which do not
penetrate well the blood brain barrier
Plasma and Brain concentration of
JBI-2174 in Balb-C mice
0 2 4 6 8
10
100
1000
10000
PO: 50 mg/Kg (Plasma)
Plasma and brain concentration profile of
JBI- 2174 in Balb C mice
Time (h)
Concentration
in
plasma/brain
Mean
±
S.D.
(ng/mL;ng/G)
PO: 50 mg/Kg (Brain)
JBT-2174 is a small molecule with the same MOA of
approved ICI but differentiate in high brain penetration
The program is in lead optimization stage to
declare a development candidate with potential
differentiation from approved ICI

34. JBI-2174 induces PD-L1 dimerization similar to approved checkpoint inhibitors
34
JBI-2174 induced dimerization of PD-L1 in cells
Crystal Structure of PD-L1 & JBI-2174
PD-L1
PD-L1
JBI-2174
Crystal structure confirms JBI-2174
induced PD-L1 dimerization in cells JBI-2174 Anti-PD-L1 Antibody

35. JBI-2174 shows strong anti-tumor activity against tumors in the brain
35
Brain tumor orthotopic model
Strong efficacy demonstrated in brain tumor orthotopic model
Note: Study performed at Dr. Dinorah Morvinsky lab, Tel Aviv University, Israel
0 10 20 30 40 50
0
50
100
Survival proportions: Ctrl vs JBI-2174
Time
Probability
of
Survival
ctrl
JBI-2174, 50 mg/kg QD
Median survival
ctrl
27
JBI-2174, 50 mg/kg QD
38
P value 0.0459

36. T-cells
CD45+/CD3+/CD4+/CD69+
Fold
change
vs.
control
C
o
n
t
r
o
l
J
B
I
-
2
1
7
4
,
3
0
m
p
k
I
s
o
t
y
p
e
c
o
n
t
r
o
l
A
n
t
i
-
P
D
-
1
A
b
0
2
4
6
8 **
Strong in vivo efficacy observed with JBI-2174 in breast cancer syngeneic model
36
4-T1 Syngeneic Model
T-cells
CD45+/CD3+/CD4+/CD69+
Comparable or better anti-tumor activity to
anti-PD1 antibody
Enhanced infiltrating activated T-lymphocytes
Days
Tumor
volume
(mm
3
)
0 5 10 15
0
500
1000
1500
Vehicle control
Isotype control
JBI 2174 30 mpk
anti-PD1 Ab
4T1 Syngeneic model

37. Recent publications
Intellectual property:
• Patent applications filed in Australia, Brazil, Canada, China, Egypt, Europe, Hong Kong, India, Indonesia, Israel, Japan, Korea,
Mexico, New Zealand, Russia, Singapore, Thailand, USA and South Africa
• Earliest filed patent application in pyrimidine series will expire on 06-Nov-37
• Earliest filed patent application filed in bicyclic compound series will expire on 13-Mar-39
PD-L1i: Recent publications, presentations, and Intellectual property
37
April 2021
AACR (American Association of Cancer Research) Annual meeting
Poster: Novel, heterocyclic small molecule inhibitors of PD-1/PD-L1 pathway

38. Epipad LLC
(PAD4
Inhibitor)
JBI-1044

39. PAD4 Inhibitor Highlights: First in class for cancer and autoimmune
Differentiation
Clinical opportunities
Efficacy
Safety
Milestones
MOA
First-in-class PAD4 inhibitors with potential to be a next generation treatment for
autoimmune disease with broad disease application including NETosis mediated tumor
metastasis. No observed immune suppression unlike JAK-2 and TNF-α
Oral, isoform selective PAD4 inhibitors
RA, fibrosis, colitis, cancer and other inflammatory indications such as hidradenitis
suppurativa (HS) and antibody associated vasculitis (AAV)
Therapeutic activity observed in multiple disease states including cancer, RA and other
autoimmune/inflammation models including diabetic wound healing and psoriasis
Promising therapeutic margin with no observed immune suppression including absence of
neutropenia, thrombocytopenia and leukopenia
IND filing in 2023
PCT patent filed in major territories and expires in 2038
39

40. Potential to address acute and chronic autoimmune indications and cancer metastasis
40
Indication SoC Unmet Need Epidemiology
Major Market
Size USD B
Rheumatoid Arthritis
TNFa inhibitors, JAK
inhibitors, Interleukin
inhibitors, Methotrexate,
Steroids
Lack of disease modifying
therapies
Prevalence – 5M
MTX PR 50% *
~29.1
2029 forecast 8 Major
Markets
Liver Metastases
(mCRC, mPancreatic,
mLung and mBladder)
Surgery, anti VEGF, anti
EGFR, immune-
checkpoint, Chemotherapy,
Chemotherapy (Hepatic
Arterial Infusion)
Curative treatment,
Overall Survival
Incidence – 120,000**
1 yr Survival - 15%**
Potential
>3 B
ANCA- Associated
Vasculitis
High-dose corticosteroids,
biologics (rituximab, anti-
TNF’s) and cytotoxic drugs
(ex, cyclophosphamide)
Serious toxic side effects -
infertility, malignancy,
infections, diabetes,
dyslipidemia and
osteoporosis
Incidence – 13,000
~0.9 B
2024 forecast 7Major
Markets
*Yu, M.B., Firek, A. & Langridge, W.H.R. Predicting methotrexate resistance in rheumatoid arthritis patients. Inflammopharmacol 26, 699–708 (2018)
**Cancer Epidemiol . 2020 Aug;67:101760
7 Major Markets (7MM) = US + 5 EU Spain, Italy, France, UK , and Germany + Japan;
8 Major Markets (8MM) = 7MM+ China

41. PAD4 platform has broad therapeutic potential
RA
Other Inflammatory/Autoimmune diseases
PAD4i
Program
Fibrosis
Colitis
Cancer
Psoriasis
PAD4 citrullination of proteins and NETosis is
implicated in the pathogenesis of several diseases
JBI PAD4 platform is validated with preclinical
proof of concept in multiple indications
HS/AAV and Cancer
Rapid proof of concept in high morbid indications
NETosis is a disease driver in AAV
In vivo efficacy in multiple tumor models
Subset of RA
RA patients that discontinue treatment due to
immune suppression
In vivo efficacy in preclinical RA model
IND
2023
IND
2023
Dual Track Clinical Program
41

42. JBI-1044 reverses disease severity in preclinical arthritis model
JBI-1044 observed to have dose-dependent
improvement in clinical score
JBI-1044 in mouse model of collagen induced arthritis
Evaluation of JBI-1044 in Mouse model of
Collagen induced arthritis
Clinical
Score
(Mean

SEM)
Day 28 Day 30 Day 31 Day 33 Day 35 Day 37 Day 39 Day 41 Day 43 Day 45
0
3
6
9
12
*P<0.05 vs Vehicle Control, Two way ANOVA followed by Bonferroni multiple comparisons Test.
*
*
*
*
*
*
*
Normal Control
JBI-1044 (3 mpk, BID, po)
JBI-1044 (6 mpk, BID, po)
JBI-1044 (12.5 mpk, QD, po)
Vehicle Control JBI-1044 protects from disease
progression and reverses disease in
collagen induced arthritis
JBI-1044 ED50 3mg/kg
42
Clinical
Score
(Mean
±
SEM)

43. PAD4i inhibits LL-2 tumor growth and metastasis
PAD4i inhibits LL2 tumor growth
PAD4i inhibits lung metastasis
PAD4i enhances activated T cells in tumor
Dr. Yulia Nefadova, Wistar Inst.
0 1 2 1 5 1 8 2 1 2 4
0
1 0 0
2 0 0
3 0 0
d a y s a fte r tu m o r In je c tio n
t
u
m
o
r
s
i
z
e
(
m
m
2
)
C ontrol
JBI-589
ICB
JBI-589+ICB
****
****
PAD4i + ICB
V e h ic le
J B I-5 8 9
0
4 .0 1 0 5
8 .0 1 0 5
1 .0 1 0
7
2 .0 1 0 7
3 .0 1 0 7
*
T
o
ta
l
F
lu
x
(p
h
o
to
n
s
/s
e
c
)
* * *
* * * *
* * *
U T
J B I-5 8 9
IC B
J B I-5 8 9 + IC B
0
1
2
3
4
5
6
%
C
D
8
+
TNF

+
* *
* *
* *
* * * *
* *
U T
J B I-5 8 9
IC B
J B I-5 8 9 + IC B
0
1
2
3
4
5
6
%
C
D
8
+
IFN

+
* * * *
* * * *
43
PAD4i
Control
ICB
Days After Tumor Injection
Tumor
Size
(mm
2
)
Total
Flux
(Photons/sec)
PAD4i
Control
PAD4i
Control
%CD8
+
TNF
+
%CD8
+
IFN
+
PAD4i
UT ICB PAD4i
+ ICB
PAD4i
UT ICB PAD4i
+ ICB
3x107
2x107
1x107
8x105
4x105

44. Recent publications
Intellectual property
• Patent applications filed in India, Australia, Brazil, Canada, China, Egypt, Europe, Hong Kong, Indonesia, Israel, Japan, Korea,
Mexico, New Zealand, Russia, Singapore, Thailand, USA and South Africa
• Earliest filed patent application in Oxa-diaza series will expire on 22-Sep-37
• Earliest filed patent application in Imidazo-pyridine series will expire on 18-Oct-37
PAD4i: Recent publications, presentations, and Intellectual property
44
March 2022
AACR (American Association of Cancer Research) Annual meeting
Poster: Novel, isoform selective PAD4 inhibitors for the treatment of
Cancer
Nov 2019
ACR (American College of Rheumatology)/ARP Annual Meeting
Poster: Novel PAD4 inhibitors for the treatment of autoimmune
disorders

45. Jubilant Therapeutics has multiple near term catalysts across its portfolio
Program Indications
2022 2023 2024
1H 2H 1H 2H 1H 2H
JBI-802
LSD1/HDAC6 Dual Inhibitor
Neuroendocrine Tumors, SCLC,
AML, MPN, MDS
JBI-778
PRMT5 Inhibitor
Glioblastoma, Brain
Metastases, MCL
JBI-2174
PD-L1 Inhibitor
Head & Neck, Brain
Metastases, GI Tract Cancers
PAD4 Inhibitor
RA, HS, Vasculitis, Liver
Metastases
Discovery Oncology
Phase I/ II
ongoing
Phase I
Initial Data
Phase I
Initial Data
Phase I
Initial Data
Phase I
Initial Data
IND
Submissions
IND/Phase I
Initiation
IND/Phase I
Initiation
IND/Phase I
Initiation
45
Phase II
Initial Data
Phase II
Initial Data